Christine I. Wooddell

机构：Arrowhead Pharmaceuticals (United States) · ORCID：0000-0002-8203-7493

发表论文 32 篇 · 总被引 1736 次 · h-index 18

代表论文

• RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg (2017 · Science Translational Medicine · 被引 490)
• Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection (2013 · Molecular Therapy · 被引 292)
• Current Status of Pharmaceutical and Genetic Therapeutic Approaches to Treat DMD (2011 · Molecular Therapy · 被引 192)
• Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent (2015 · Antiviral Research · 被引 130)
• Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease (2020 · JCI Insight · 被引 59)
• Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes (2014 · Methods in molecular biology · 被引 51)